DoseMe Appoints Richard Malone, PharmD, MHA, as Vice President, Clinical & Science. March 11, 2026 Seasoned pharmacy and healthcare technology leader to oversee clinical strategy, biostatistics and scientific innovation JUPITER, FL- March 12, 2026 - DoseMe, a global leader in model-informed precision dosing (MIPD) software, today announced the appointment of Richard Malone, PharmD, MHA, as Vice President, Clinical & Science. In this role, Malone will lead the company's clinical and scientific initiatives, including oversight of biostatistics, clinical content development, and alignment of scientific strategy with DoseMe's broader growth objectives, including integration of newly acquired capabilities from Firstline. The combined platform of DoseMe and Firstline unifies evidence-based antimicrobial selection with Bayesian model-informed precision dosing within a single, streamlined clinical workflow. Together, the integrated solution enables health systems to align stewardship strategy, prescribing guidance, and individualized dosing optimization to improve outcomes, reduce resistance risk, and enhance operational efficiency. "Richard's unique combination of frontline clinical expertise, operational leadership, and healthcare technology experience strengthens DoseMe's ability to deliver scientifically rigorous, clinically practical precision dosing solutions," said John Hardesky, CEO of DoseMe. "As we expand our platform with the integration of Firstline's clinical decision support capabilities, his leadership positions us to further advance Bayesian modeling and unified antimicrobial stewardship solutions for health systems worldwide." Malone brings more than 30 years of leadership experience spanning hospital pharmacy operations, investigational drug services, healthcare software, and executive sales leadership. Malone will manage the team of biostatisticians responsible for building and advancing clinical models within the DoseMe platform and serve as the company liaison to the DoseMe Clinical Advisory Board. He will also play a key role in ensuring alignment between scientific innovation and the company's strategic roadmap. "I'm excited to join DoseMe at a time when precision dosing and model-informed drug therapy are becoming central to modern antimicrobial stewardship and patient safety," said Malone. "I look forward to strengthening the company's scientific foundation while supporting scalable growth." Most recently, Malone served as Vice President, Sales at Inovalon, where he led the Care Management business unit's national sales operations. Under his leadership, the team accelerated growth to $3.6 million in new annual contract value in 2024 and achieved greater than 100% net revenue retention, followed by 140% year-over-year ARR growth in the first half of 2025. Prior to Inovalon, Malone was president of McCreadie Group LLC, a healthcare software company acquired by Cordance Operations. During his tenure, the organization achieved 24% year-over-year growth and 28% EBITDA, while expanding its SaaS solutions supporting pharmaceutical research sites and pharmacy residency programs. Malone also brings deep academic medical center experience. He served for nearly a decade as Program Director of the Investigational Drug Service at Vanderbilt University Medical Center, where he led consolidation and expansion of research pharmacy services across the enterprise, improved quality metrics to over 99%, and transitioned the department to a positive operating margin within 12 months. Earlier in his career, he held executive pharmacy leadership roles including Director of Pharmacy at Centennial Medical Center and Maury Regional Medical Center, as well as Corporate Director of Pharmacy Operations for Vanguard Health Systems, overseeing pharmacy strategy across a 25-hospital system. Malone earned his Doctor of Pharmacy with honors from the University of Tennessee College of Pharmacy and a Master of Science in Health Care Administration from the University of Maryland University College. He completed his Pharmacy Practice Residency at Saint Thomas Hospital in Nashville, Tennessee. About DoseMe DoseMe is the provider of Firstline and DoseMeRx clinical decision support technologies that enable proactive, personalized care. Firstline is a mobile-first platform making treatment guidance accessible to every clinician, anywhere. DoseMeRx delivers clinically validated PK/PD models to individualize precision dosing in seconds. DoseMe's evidence-based clinical intelligence helps reduce adverse drug events, antibiotic overuse, improved adherence to stewardship guidance, and provides clinicians a clear path to optimal care. For more information and real-world success stories, visit https://doseme-rx.com/success-stories * News briefs American Journal of Health-System Pharmacy, 2021 * ASHP Executive Forums on Cold Chain Management of Pharmaceuticals in Health Systems American Journal of Health-System Pharmacy * SITC Appoints James Gulley as Vice President ASH Clinical News, 2022 * ASHP Distinguished Leadership Award Kate Traynor, American Journal of Health-System Pharmacy, 2022 * Appointment American Journal of Health-System Pharmacy, 2021

Cordance has acquired AppsAnywhere to enhance software access and delivery in higher education IT. This acquisition aims to expand capabilities in application delivery and IT efficiency, promoting digital equity for students. AppsAnywhere, trusted by over 300 institutions, will align with LabStats, another Cordance company, to optimize software delivery and usage analytics. This move supports higher education leaders in meeting diverse student expectations and improving IT efficiencies.

Blue Link Associates Limited, the all-in-one, wholesale distribution inventory management and accounting software system, partners with Cordance for growth